+387 51 456 040 Send us an e-mail How to reach us?

Cooperation



Flag Counter

Medicinal products are one of the most regulated areas of legal legacy of European Union. Agency for medicinal products and medical devices of Bosnia and Herzegovina conducts intensive international cooperation so it would be prepared to function in integrated and regulated area/environment, when Bosnia and Herzegovina becomes a member of European Union.

As part of IPA-project (Instrument for Pre-Accession Assistance), in which are candidate countries and potential candidates for membership in EU, Agency’s experts participate as observers in certain boards and working groups of European Medicines Agency (EMA). Cooperation with EMA has started in 2009 and it is still current.

The Agency also cooperates with European Directorate for the Quality of Medicines & HealthCare (EDQM), which is part of Council of Europe in Strasbourg. The Agency participates in work of European Commission for pharmacopoeia, as in activities European Official Medicines Control Laboratories Network (OMCL Network), which includes conducting of inter-laboratory testing.

The Agency conducts intensive cooperation with regulatory bodies for medicinal products and medical devices in countries of region. Until now have been signed protocols of cooperation with the Medicines and Medical Devices Agency of Serbia (ALIMS), the Agency of Medicines and Medical Devices of Montenegro (CALIMS) and with Agency for Medicinal Products and Medical Devices of Croatia (HALMED).

The Agency has also signed contracts / agreements in the field of providing professional service within the scope / capacity of the Pharmacovigilance Head Office in Mostar with the Institute of Pharmacology of University-Clinical Centre in Banja Luka and the Centre of medicinal products of University-Clinical Centre of Sarajevo.

During our work, significant help and support have been provided to us by World Health Organization (WHO) – office in B-H, by organizing continuing / advancing trainings of several days in domain of pharmaceutical law.